Notably, reduced AR pathway activity is a necessary condition for resistance to AR signaling inhibitors (186); in addition, PMN-MDSCs can promote resistance to AR signaling inhibitors by activating AR-V7 (27), while KIF15 can enhance the resistance of tumor cells to enzalutamide by stabilizing the protein levels of AR/AR-V7 (184). Here, AR is linked to neoplasm.